Tagraxofusp comparable to other chemo regimens as first-line therapy
September 04, 2020

Findings from a recent study support current recommendations to treat patients with BPDCN with tagraxofusp or hyper-CVAD as first-line treatments, then with allogeneic stem cell transplant if patients are eligible.

What dermatologists should know about blastic plasmacytoid dendritic cell neoplasm
September 03, 2020

One expert who is part of a small worldwide group of dedicated scientists and clinicians working to build BPDCN awareness among specialists offers insights from his research for dermatologists.

FDA-approved treatment puts rare cancer with skin manifestations on the map
July 31, 2020

Those who study blastic plasmacytoid dendritic cell neoplasm (BPDCN) struggle to make dermatologists and others aware that the rare hematologic malignancy that often first presents with skin manifestations exists.

Tagraxofusp: efficacy, safety and unanswered questions
July 29, 2020

Tagraxofusp, the first and only FDA-approved drug for blastic plasmacytoid dendritic cell neoplasm (BPDCN), outperforms traditional chemotherapy treatment for the rare myeloid malignancy.

Anti-CD123-CAR T-cell therapy-radiotherapy combo effectively treats recurring blastic plasmacytoid dendritic cell neoplasm
July 14, 2020

The 10-year-old male presented after experiencing five months of bilateral knee joint pain. A bone marrow smear and biopsy revealed the boy had blastic plasmacytoid dendritic cell neoplasm. Doctors treated him and the patient achieved complete remission. The patient presented with a scalp rash one month after his first complete remission.

Review highlights inroads to understanding blastic plasmacytoid dendritic cell neoplasm
July 13, 2020

Studies are revealing clinical, molecular, diagnostic and therapeutic findings that are leading to a better understanding of blastic plasmacytoid dendritic cell neoplasm, and there are promising targeted treatments in the pipeline as well as a growing social media interest.

BPDCN patients at increased risk of second primary malignancies
June 01, 2020

Rare aggressive cutaneous lymphoma puts patients at risk of thyroid and non-lymphocytic leukemia second primary malignancies, researchers say.

Genetic features pave way for targeted BPDCN therapies
June 01, 2020

Dermatologists might be the first providers to encounter patients with blastic plasmacytoid dendritic cell neoplasm because more than 70% of these patients have cutaneous lesions. With one approved treatment and several in clinical trials, there are promising and much needed therapeutic options coming.

Investigational agents to treat hematologic malignancy in pipeline
May 04, 2020

Blastic plasmacytoid dendritic neoplasm (BPDCN) is a rare but aggressive hematologic malignancy that often manifests with asymptomatic skin lesions that often appear as bruise-like lesions, plaques or nodules. With one approved drug available, researchers are studying additional investigational agents.

Consider lesion biopsy in patients with history of certain cancers
May 04, 2020

While little is known about BPDCN  and how to treat it, authors of a recent study suggest a low threshold for performing a skin biopsy to evaluate skin lesions in patients with hematological cancers, especially when those lesions that are quickly progressing, large or involve atypical sites.